(Reuters) - Pfizer Inc and Eli Lilly and Co said they planned to resume a late-stage study testing their pain drug tanezumab after the U.S. Food and Drug Administration lifted a partial hold on it. Pfizer expects to receive a $200 million upfront payment from Lilly as a result of the development, the companies said on Monday. The FDA put tanezumab and all other anti-nerve growth factor antibodies on a partial clinical hold since December 2012. (Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb Chakrabarty)
March 23, 2015 at 08:20AM
via Lazahealth.org
No comments:
Post a Comment